DarioHealth Corp. (DRIO)
NASDAQ: DRIO · Real-Time Price · USD
0.755
+0.045 (6.31%)
At close: Jan 22, 2025, 4:00 PM
0.720
-0.035 (-4.61%)
Pre-market: Jan 23, 2025, 8:00 AM EST
DarioHealth Revenue
DarioHealth had revenue of $7.42M in the quarter ending September 30, 2024, with 111.00% growth. This brings the company's revenue in the last twelve months to $23.05M, down -2.09% year-over-year. In the year 2023, DarioHealth had annual revenue of $20.35M, down -26.41%.
Revenue (ttm)
$23.05M
Revenue Growth
-2.09%
P/S Ratio
1.20
Revenue / Employee
$78,408
Employees
294
Market Cap
28.82M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 20.35M | -7.30M | -26.41% |
| Dec 31, 2022 | 27.66M | 7.14M | 34.82% |
| Dec 31, 2021 | 20.51M | 12.94M | 170.76% |
| Dec 31, 2020 | 7.58M | 17.00K | 0.22% |
| Dec 31, 2019 | 7.56M | 165.00K | 2.23% |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
| Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 400.28B |
| Johnson & Johnson | 87.70B |
| Merck & Co. | 63.17B |
| AbbVie | 55.53B |
| AstraZeneca | 51.21B |
| Novartis AG | 49.94B |
| Thermo Fisher Scientific | 42.37B |
| Abbott Laboratories | 41.22B |
DRIO News
- 1 day ago - DarioHealth Announces $25.6M Private Placement Positioning the Company to Execute on Strategy Aiming to Reach Operational Cash Flow Positive Run Rate by the End of 2025 - PRNewsWire
- 8 days ago - DarioHealth Expands GLP-1 Weight-Loss Solution, Unlocking New Revenue Streams in Rapidly Growing Multi Billion Dollar Market - Business Wire
- 8 days ago - DarioHealth Expands GLP-1 Solution with Prescribing Capabilities through Collaboration with MediOrbis, Targeting Employers and Direct-to-Consumer Markets - PRNewsWire
- 2 months ago - Dario Signs Four New Employer Contracts Across Full Product Suite - PRNewsWire
- 2 months ago - DarioHealth Corp. (DRIO) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 2 months ago - DarioHealth Reports Third Quarter 2024 Financial and Operating Results - PRNewsWire
- 2 months ago - Dario Expands Pharma Collaborations with Global Pharma Leader to Enhance User Engagement - PRNewsWire
- 3 months ago - Dario Signs New Regional Health Plan, Expanding Reach in Medicaid Population - PRNewsWire